Compliance certificate for dematerialization of securities for Q1 FY27
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
BAL Pharma submitted a routine compliance certificate under SEBI (Depositories and Participants) Regulation 74(5) to NSE and BSE, based on a report from its registrar and transfer agent MUFG Intime India. The filing confirms that details of shares dematerialised or rematerialised during the quarter ended 30 June 2026 were shared with the stock exchanges within the prescribed timeline, and that physical share certificates received for dematerialisation were mutilated, cancelled, and the depository was recorded as the registered owner within 15 days.
Routine regulatory compliance filing with no material impact on the business, financials, or share price.